SERVICES
 SEARCH
HISTOLOGY ONCOLOGY SIDE EFFECTS
NEUROPATHY
DIABETIC PAINFUL NEUROPATHY
DIABETIC PAINFUL NEUROPATHY in the rat
INTRODUCTION
Polyneuropathy is the most common complication of diabetes for which there is no available treatment apart from therapy that normalizes glucose metabolism. About 20% of diabetes patients suffer from neuropathic pain, especially those with poorly controlled blood glucose. The streptozotocin (STZ) diabetic rat is the most extensively studied animal model of diabetic painful neuropathy. Within few days, hyperglycemia develops and clinical sign of pain (hyperalgesia) can be evidenced within 3 weeks post-STZ. Hyperalgesia seen in this model is reversed by the standard pain relief such as morphine.
COMPOUND TESTING
Compound testing addresses the effect of single treatment of diabetic rats (typically within 1 hour before the monitoring) on:

- Inhibition of mechanical hyperalgesia (paw pressure using Randall & Sellito instrument).
Reversion of mechanical hyperalgesia by morphine in STZ-rats.
REFERENCES
Greene DA, Sima AA, Feldman EL, Stevens MJ. Ellenberg and Rifkin diabetic neuropathy. In: Rifkin H, Porte D, Sherwin R (ed.) Diabetes Mellitus. Stanford CT: Appleton and Lange, 1997;1009-1076.
Calcutt, N.A., 2002. Potential mechanisms of neuropathic pain states.
Int. Rev. Neurobiol. 50, 205-228.
Sima AA. New insights into the metabolic and molecular basis for diabetic neuropathy.
Cell Mol Life Sci 2003; 60: 2445-2464.
Courteix, C., Bardin, M., Chantelauze, C., Lavarenne, J., Eschalier, A., 1994. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics.
Pain 57, 153-160.
Boulevard S. Brant
BIOPARC - 67 400
ILLKIRCH-FRANCE
Tel:
 +33(0)388651606
Fax:
 +33(0)388651622